# Plain Language Summary: Drug Competition Enhancement Act

This bill is designed to make it easier for generic and biosimilar drugs to enter the market and compete with brand-name medications. Right now, pharmaceutical companies can use various legal strategies to delay competition, which keeps drug prices high. This bill aims to close some of those loopholes and speed up the process for cheaper alternative versions of drugs to become available to patients.

The main way it does this is by limiting how long drug companies can use certain legal tactics to block competitors. For example, when a brand-name drug company gets a patent, they can sometimes file multiple lawsuits or use other legal maneuvers to prevent generic versions from being sold, even after their original patent expires. This bill would restrict those delay tactics, meaning generic drug makers could get their products to pharmacies faster. It also likely includes measures to make the approval process for generic and biosimilar drugs more straightforward, reducing unnecessary bureaucratic hurdles.

Who does this affect? Patients and consumers would potentially benefit the most through lower drug prices, since generic drugs are typically much cheaper than brand-name versions. Insurance companies and government programs like Medicare would also save money. On the flip side, brand-name pharmaceutical companies would face more competition sooner, which could reduce their profits. The bill essentially tries to balance the interests of drug makers with the need to keep medications affordable for everyday people.

Drug Competition Enhancement Act

Cornyn, John

Drug Competition Enhancement Act This bill prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission (FTC) to enforce this prohibition.Generally, product&nbsp;hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantively similar to an indication of the reference drug.The bill establishes a presumption that product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product.A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.The bill makes product hopping an unfair method of competition and provides for enforcement by the FTC. If the FTC has reason to believe a manufacturer has violated or is about to violate this prohibition on product hopping, the FTC may institute an administrative proceeding or bring suit in federal court to stop the manufacturer’s action and seek equitable remedies, including disgorgement of unjust profits or paying restitution to those harmed.&nbsp;